Literature DB >> 12147298

Substrate-dependent, non-hyperbolic kinetics of pig brain prolyl oligopeptidase and its tight binding inhibition by JTP-4819.

Jarkko I Venäläinen1, Risto O Juvonen, Markus M Forsberg, Arturo Garcia-Horsman, Antti Poso, Erik A A Wallen, Jukka Gynther, Pekka T Männistö.   

Abstract

Prolyl oligopeptidase (POP) is a cytosolic serine protease that hydrolyses small peptides at the carboxyl end of the proline residue. It has raised pharmaceutical interest, since its inhibitors have been shown to have antiamnesic properties. We studied prolyl oligopeptidase kinetics with two 7-amino-4-methylcoumarin derivatives: Z-Gly-Pro-AMC and Suc-Gly-Pro-AMC. Z-Gly-Pro-AMC was found to obey standard Henri-Michaelis-Menten kinetics with a K(m) of 30+/-3 microM, whereas Suc-Gly-Pro-AMC exhibited substrate inhibition kinetics with K(m) and K(is) of 510+/-150 and 270+/-90 microM, respectively. Autodock simulations revealed that either the succinyl or the AMC-end of Suc-Gly-Pro-AMC may bind to the S'1 subsite of the active site. We believe that non-specifically bound Suc-Gly-Pro-AMC allows the simultaneous binding of second substrate molecule to the active site and this leads in substrate inhibition. In addition, we demonstrated that the inhibition type of a well characterized prolyl oligopeptidase inhibitor, JTP-4819, is competitive tight binding with a K(ic) of 0.045+/-0.008 nM. We suggest that due to the high concentration of prolyl oligopeptidase in the brain (0.12 nmol/g pig brain), the tight binding nature of the inhibition should be considered when using brain homogenate as the enzyme source in prolyl oligopeptidase inhibition measurements. This is of importance in studying structure-activity relationships of potent prolyl oligopeptidase inhibitors.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12147298     DOI: 10.1016/s0006-2952(02)01184-x

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN: 0006-2952            Impact factor:   5.858


  9 in total

1.  Tetrazole as a Replacement of the Electrophilic Group in Characteristic Prolyl Oligopeptidase Inhibitors.

Authors:  Tommi P Kilpeläinen; Jonna K Tyni; Maija K Lahtela-Kakkonen; Tony S Eteläinen; Timo T Myöhänen; Erik A A Wallén
Journal:  ACS Med Chem Lett       Date:  2019-11-11       Impact factor: 4.345

2.  Enhancement of fibrinolysis by inhibiting enzymatic cleavage of precursor α2-antiplasmin.

Authors:  K N Lee; K W Jackson; V J Christiansen; E K Dolence; P A McKee
Journal:  J Thromb Haemost       Date:  2011-05       Impact factor: 5.824

Review 3.  Post-Proline Cleaving Enzymes (PPCEs): Classification, Structure, Molecular Properties, and Applications.

Authors:  Anis Baharin; Tiew-Yik Ting; Hoe-Han Goh
Journal:  Plants (Basel)       Date:  2022-05-18

4.  Distribution of prolyl oligopeptidase in human peripheral tissues and in ovarian and colorectal tumors.

Authors:  Timo T Myöhänen; Elisa Pyykkö; Pekka T Männistö; Olli Carpen
Journal:  J Histochem Cytochem       Date:  2012-06-26       Impact factor: 2.479

5.  Distribution of prolyl oligopeptidase in the mouse whole-body sections and peripheral tissues.

Authors:  Timo T Myöhänen; Jarkko I Venäläinen; J Arturo García-Horsman; Marjo Piltonen; Pekka T Männistö
Journal:  Histochem Cell Biol       Date:  2008-07-11       Impact factor: 4.304

6.  Slow-binding inhibitors of prolyl oligopeptidase with different functional groups at the P1 site.

Authors:  Jarkko I Venäläinen; Risto O Juvonen; J Arturo Garcia-Horsman; Erik A A Wallén; Johannes A M Christiaans; Elina M Jarho; Jukka Gynther; Pekka T Männistö
Journal:  Biochem J       Date:  2004-09-15       Impact factor: 3.857

7.  Nature of action of Sitagliptin, the dipeptidyl peptidase-IV inhibitor in diabetic animals.

Authors:  Joseph A Davis; Shuchita Singh; Sachin Sethi; Subhasis Roy; Shivani Mittra; Geetavani Rayasam; Vinay Bansal; Jitendra Sattigeri; Abhijit Ray
Journal:  Indian J Pharmacol       Date:  2010-08       Impact factor: 1.200

8.  Biological evaluation of RBx-0128, a potent and selective dipeptidyl peptidase-IV inhibitor in type 2 diabetes genetic model.

Authors:  Joseph A Davis; Pucha S Kumar; Shuchita Singh; A Surender; Subhasis Roy; Vivek Khanna; Sachin Sethi; Chanchan Pal; Lalima Sharma; Biju Benjamin; Shivani Mittra; Jitendra Sattigeri; Vinay S Bansal
Journal:  Indian J Pharmacol       Date:  2012 Nov-Dec       Impact factor: 1.200

9.  Cyclotides Isolated From Violet Plants of Cameroon Are Inhibitors of Human Prolyl Oligopeptidase.

Authors:  Jasmin Gattringer; Olivier Eteme Ndogo; Bernhard Retzl; Carina Ebermann; Christian W Gruber; Roland Hellinger
Journal:  Front Pharmacol       Date:  2021-07-12       Impact factor: 5.810

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.